---
title: "LUMIFOLLOW one-year outcomes show efficacy for femoropopliteal lesions"
date: "2024-01-10T12:24:59.000Z"
publishedDate: "10 janvier 2024"
summary: "Luminor (iVascular) drug-coated balloon (DCB) has confirmed its excellent safety and efficacy in femoropopliteal lesions with new study LUMIFOLLOW, a recent press release states. iVascular presented at Paris Vascular Insights (PVI) 2023 (8–10 November, Paris, France), delivering one year outcomes of the prospective, multicentre, consecutive, post-market study LUMIFOLLOW."
importance: ""
sourceUrl: "https://interventionalnews.com/lumifollow-one-year-outcomes-show-efficacy-for-femoropopliteal-lesions/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2024-01-10-lumifollow-one-year-outcomes-show-efficacy-for-femoropopliteal-lesions"
imageUrl: "https://interventionalnews.com/wp-content/uploads/sites/13/2024/01/BIBLIOS-AND-EFFPAC-TRIAL-PRESS-RELEASE.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/lumifollow-one-year-outcomes-show-efficacy-for-femoropopliteal-lesions/"
---

![LUMIFOLLOW one-year outcomes show efficacy for femoropopliteal lesions](https://interventionalnews.com/wp-content/uploads/sites/13/2024/01/BIBLIOS-AND-EFFPAC-TRIAL-PRESS-RELEASE.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/lumifollow-one-year-outcomes-show-efficacy-for-femoropopliteal-lesions/*

## L’essentiel

Luminor (iVascular) drug-coated balloon (DCB) has confirmed its excellent safety and efficacy in femoropopliteal lesions with new study LUMIFOLLOW, a recent press release states. iVascular presented at Paris Vascular Insights (PVI) 2023 (8–10 November, Paris, France), delivering one year outcomes of the prospective, multicentre, consecutive, post-market study LUMIFOLLOW.

## Lien source

https://interventionalnews.com/lumifollow-one-year-outcomes-show-efficacy-for-femoropopliteal-lesions/
